RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade

Retinoic acid-inducible gene-I (RIG-I) is a cytoplasmic immune receptor sensing viral RNA. It triggers the release of type I interferons (IFN) and proinflammatory cytokines inducing an adaptive cellular immune response. We investigated the therapeutic potential of systemic RIG-I activation by short...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruzicka, Michael, Koenig, Lars M., Formisano, Simone, Boehmer, Daniel F. R., Vick, Binje, Heuer, Eva-M., Meinl, Hanna, Kocheise, Lorenz, Zeitlhöfler, Marcus, Ahlfeld, Julia, Kobold, Sebastian, Endres, Stefan, Subklewe, Marion, Duewell, Peter, Schnurr, Max, Jeremias, Irmela, Lichtenegger, Felix S., Rothenfusser, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214254/
https://www.ncbi.nlm.nih.gov/pubmed/31740809
http://dx.doi.org/10.1038/s41375-019-0639-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214254/
https://www.ncbi.nlm.nih.gov/pubmed/31740809
http://dx.doi.org/10.1038/s41375-019-0639-x

Ejemplares similares